WESTMINSTER, Colo., Oct. 31 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (Nasdaq: ALTH) today announced that data evaluating the
Company's product candidates EFAPROXYN (efaproxiral) and PDX (pralatrexate)
have been accepted for presentation at the following scientific
conferences:
* American Society for Therapeutic Radiology and Oncology: Hak Choy,
M.D., Chairman, Department of Radiation Oncology, University of Texas
Southwestern Medical Center, is scheduled to present an updated
survival analysis of data from a Phase 2 trial of EFAPROXYN in patients
with locally advanced (Stage IIIA/B) non-small cell lung cancer in an
oral presentation titled "Comparison of 5-Year Survival Between
RTOG-94-10 and a Phase 2 Study of Induction Chemotherapy Followed by
Efaproxiral + Radiotherapy in Patients with Locally Advanced NSCLC" on
Monday, November 6. In addition, Huagang Hou, M.D., Research Assistant
Professor of Radiology, Dartmouth Medical School, is scheduled to
report findings from a pre-clinical study of EFAPROXYN in a slide
presentation titled "Effects of repeated EFAPROXYN (TM) (efaproxiral)
dosing, an allosteric hemoglobin modifier, on oxygenation and
enhancement of radiotherapy in subcutaneous RIF-1 tumors, in mice" on
Tuesday, November 7.
* EORTC-NCI-AACR International Conference on Molecular Targets and Cancer
Therapeutics: Owen O'Connor, M.D., Ph.D., Head of the Laboratory of
Experimental Therapeutics for Lymphoproliferative Malignancies,
Lymphoma and Development Chemotherapy Services, Memorial
Sloan-Kettering Cancer Center, is scheduled to present updated data
from an on-going Phase 1/2 study of PDX in patients with relapsed or
refractory non-Hodgkin's lymphoma and Hodgkin's disease in a poster
presentation titled "Clinical Experience with Pralatrexate
(10-Propargyl-10-deazaaminopterin (PDX)), a Novel Antifolate with High
Affinity for the Reduced Folate Carrier, in Patients with Chemotherapy
Refractory Lymphoproliferative Malignancies" on Friday, November 10.
Copies of the posters will be available on the Company's website,
http://www.allos.com, the day following each presentation and will be archived for
30 days.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused
on the development and commercialization of small molecule therapeutics for
the treatment of cancer. The Company has two product candidates in
late-stage clinical development: EFAPROXYN (efaproxiral), a radiation
sensitizer currently under evaluation in a pivotal Phase 3 trial in women
with brain metastases originating from breast cancer, and PDX
(pralatrexate), a novel, next generation antifolate currently under
evaluation in a pivotal Phase 2 trial in patients with relapsed or
refractory peripheral T-cell lymphoma. The Company is also evaluating RH1,
a targeted chemotherapeutic agent, in a Phase 1 trial in patients with
advanced solid tumors. For additional information, please visit the
Company's website at http://www.allos.com.
Safe Harbor Statement
The anticipated presentations will contain forward-looking statements
that involve significant risks and uncertainties, including those to be
discussed in the presentation and others that can be found in the "Risk
Factors" section of the Company's Form 10-K for the year ended December 31,
2005 and in the Company's periodic reports on Form 10-Q and Form 8-K. The
Company does not undertake any obligation to update any forward-looking
statements contained in the anticipated presentation as a result of new
information, future events or otherwise. The Company cautions investors not
to place undue reliance on the forward-looking statements contained in the
presentation. No forward-looking statement can be guaranteed and actual
events and results may differ materially from those projected.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com
CONTACT:
Jennifer Neiman Manager, Corporate
Communications of Allos Therapeutics, +1-720-540-5227,
jneiman@allos.com
|
